MetaVia Inc. (MTVA): Insider Trading, Congress Trades & Research | Tormere

MTVA

$1.34+6.35%visit website

MetaVia Inc.

Market Cap

$9M

Live price × SEC shares (Aug 3, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.20

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

1.3

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	1,914	241	2,101	3,478	7,734
Total operating expenses	3,475	2,046	4,025	5,385	14,931
Operating income	(3,475)	(2,046)	(4,025)	(5,385)	(14,931)
Pretax income	(3,377)	(1,930)	(3,823)	(5,316)	(14,446)
Income tax	0.00	0.00	0.00	0.00	0.00
Net income	(3,377)	(1,930)	(3,823)	(5,316)	(14,446)
EPS (basic) ($)	(0.14)		(0.79)	(0.90)	—
EPS (diluted) ($)	(0.14)		(0.79)	(0.90)	—
Weighted avg. shares (basic)	24,416		4,860	5,932
Weighted avg. shares (diluted)	24,416		4,860	5,932

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 6, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 42 more quarters, back to Mar 2015, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026

Yahoo · 2026-10-28

MetaVia To Report Data From Its Phase 1 Clinical Study Of DA-1726 At Precision Liver Symposium 2026

Benzinga · 2026-10-28

12 Health Care Stocks Moving In Monday's After-Market Session

Benzinga · 2026-10-26

MTVA: MetaVia Inc. Latest Stock Price, Analysis, News and Trading Ideas

Stocktwits · 2026-10-16

MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer

Yahoo · 2026-10-13

MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction

Yahoo Finance · 2026-09-10

MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction

Yahoo Finance · 2026-09-09

MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726

Yahoo Finance · 2026-08-12

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Yahoo Finance · 2026-08-06

MTVA Stock Jumps As Obesity Drug Trial Hits Key Milestone

timothysykes.com · 2026-07-13

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Yahoo Finance · 2026-07-09

OTC Markets Life Sciences Investor Forum: MetaVia CEO HH Kim and CFO Marshall Woodworth with Zacks SCR's David Bautz

Yahoo Finance · 2026-06-30

MTVA Forecast — Price Target — Prediction for 2027

TradingView · 2026-06-26

MTVA Stock Price and Chart — NASDAQ:MTVA

TradingView · 2026-06-06

Why MetaVia Stock Is Falling On Thursday? - MetaVia (NASDAQ:MTVA)

Benzinga · 2026-05-21

Informational purposes only, not investment advice.